Zanamivir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Zanamivir |
| DrugBank ID | DB00558 |
| Brand Names (EU) | Dectova |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.84% |
Approved Indication (EMA)
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pyelonephritis | 99.84% | DL |
| 2 | influenza, severe, susceptibility to | 99.42% | DL |
| 3 | disorder of tyrosine metabolism | 99.02% | DL |
| 4 | teratogenic Pierre Robin syndrome | 98.94% | DL |
| 5 | disorder of phenylalanine metabolism | 98.86% | DL |
| 6 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | 98.41% | DL |
| 7 | susceptibility to HIV infection | 98.40% | DL |
| 8 | dengue virus, susceptibility to | 98.40% | DL |
| 9 | legionnaire disease, susceptibility to | 98.40% | DL |
| 10 | aspergillosis, susceptibility to | 98.40% | DL |
| 11 | Schistosoma mansoni infection, susceptibility | 98.35% | DL |
| 12 | influenza | 98.17% | DL |
| 13 | cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency | 98.13% | DL |
| 14 | staphylococcus aureus infection | 97.91% | DL |
| 15 | pyogenic bacterial infections due to MyD88 deficiency | 97.83% | DL |
| 16 | acute hemorrhagic encephalitis | 97.78% | DL |
| 17 | acute necrotizing encephalitis | 97.76% | DL |
| 18 | HHV-6 encephalitis | 97.76% | DL |
| 19 | Hendra virus infection | 97.76% | DL |
| 20 | equine encephalitis | 97.64% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.